Assays aimed at evaluating amyloid beta (Aβ) and phosphorylated tau (p‐tau) levels with positron emission tomography (PET)–based tracers or from biological fluids are valuable for the early diagnosis of AD, for monitoring, and for distinguishing the condition from other forms of dementia.3 This evidence concerns the gene MAPT and Alzheimer disease.